Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Go back to Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 197.74 -5.42 (2.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $203.16 | 52 Week High | $333.65 | |||
| Open | $203.70 | 52 Week Low | $223.02 | |||
| Day High | $204.31 | P/E | 25.32 | |||
| Day Low | $197.40 | EPS | $7.81 | |||
| Volume | 841,352 | |||||
| (NASDAQ: STOK) | Delayed: 28.96 +0.15 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.81 | 52 Week High | $ | |||
| Open | $28.57 | 52 Week Low | $ | |||
| Day High | $29.23 | P/E | N/A | |||
| Day Low | $27.96 | EPS | $ | |||
| Volume | 416,626 | |||||
